Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: A 13-year follow-up

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 234-239

  Jensen, K E ^a   Schmiedel, S ^a   Norrild, B ^b   Frederiksen, K ^a   Iftner, T ^c   Kjaer, S K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cervical intraepithelial neoplasia; intrauterine devices; oral contraceptives; parity; persistent human papillomavirus infection; sexual behaviour

Indexed keywords

ARTICLE; CANCER GRADING; FEMALE; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PAPILLOMAVIRUS INFECTION; PARITY; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCTIVE HISTORY; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONTRACEPTION; DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PARITY; SEXUAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84872618661     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.513     Document Type: Article

References (33)

1. Almonte M, Ferreccio C, Gonzales M, Delgado JM, Buckley CH, Luciani S, Robles SC, Winkler JL, Tsu VD, Jeronimo J, Cuzick J, Sasieni P (2011) Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru. Int J Gynecol Cancer 21: 1654-1663.
2. Appleby P, Beral V, Berrington de Gonzáles A, Colin D, Franceschi S, Green J, la Vecchia C, Peto J, Plummer M, Randi G, Sweetland S (2006) Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16, 563 women with cervical carcinoma and 33, 542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 119: 1108-1124.
3. Appleby P, Beral V, Berrington de Gonzáles A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16, 573 women with cervical cancer and 35, 509 women without cervical cancer from 24 epidemiological studies. Lancet 370: 1609-1621.
4. Appleby P, Beral V, Berrington de Gonzáles A, Colin D, Franceschi S, Green J, la Vecchia C, Peto J, Plummer M, Sweetland S (2009) Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15, 461 women with cervical carcinoma and 29, 164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev 18: 1060-1069.
5. Autier P, Coibion M, Huet F, Grivegnee AR (1996) Transformation zone location and intraepithelial neoplasia of the cervix uteri. Br J Cancer 74: 488-490.
6. Bobák M, Hertzman C, Škodová Z, Marmot M (2000) Own education, current conditions, parental material circumstances, and risk of myocardial infarction in a former communist country. J Epidemiol Community Health 54: 91-96.
7. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244-265.
8. Castellsague X, Bosch FX, Munoz N (2002) Environmental co-factors in HPV carcinogenesis. Virus Res 89: 191-199.
9. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98: 303-315.
10. Castellsague X, Diaz M, Vaccarella S, de Sanjose S, Munoz N, Herrero R, Franceschi S, Meijer CJ, Bosch FX (2011) Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol 12: 1023-1031.
11. Castle PE (2004) Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 8: 224-230.
12. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M (2002) A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 94: 1406-1414.
13. Castle PE, Walker JL, Schiffman M, Wheeler CM (2005) Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer 117: 1007-1012.
14. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, Peto J (2000) Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 83: 1565-1572.
15. Delvenne P, Herman L, Kholod N, Caberg JH, Herfs M, Boniver J, Jacobs N, Hubert P (2007) Role of hormone cofactors in the human papillomavirus-induced carcinogenesis of the uterine cervix. Mol Cell Endocrinol 264: 1-5.
16. Ferrera A, Velema JP, Figueroa M, Bulnes R, Toro LA, Claros JM, de BO, Melchers WJ (2000) Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol 29: 817-825.
17. Gargano JW, Nisenbaum R, Lee DR, Ruffin MT, Steinau M, Horowitz IR, Flowers LC, Tadros TS, Birdsong G, Unger ER (2012) Age-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopy. Cancer Epidemiol Biomarkers Prev 21: 111-121.
18. Gariglio P, Gutierrez J, Cortes E, Vazquez J (2009) The role of retinoid deficiency and estrogens as cofactors in cervical cancer. Arch Med Res 40: 449-465.
19. Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, Lorincz AT, Burk RD, Morales J, Rodriguez AC, Helgesen K, Alfaro M, Hutchinson M, Balmaceda I, Greenberg M, Schiffman M (2001) HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 84: 1219-1226.
20. Iftner T, Villa LL (2003) Chapter 12: human papillomavirus technologies. J Natl Cancer Inst Monogr 80-88.
21. Jensen KE, Schmiedel S, Frederiksen K, Norrild B, Iftner T, Kjaer SK (2012) Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to smoking among women with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 21: 1959-1965.
22. Kjaer S, Høgdall E, Frederiksen K, Munk C, van den BA, Svare E, Meijer C, Lorincz A, Iftner T (2006) The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66: 10630-10636.
23. Kjaer SK (2007) Human papillomavirus (HPV) infection, cervical cancer and vaccination against HPV: a Nordic perspective. Acta Obstet Gynecol Scand 86: 1286-1289.
24. Kjaer SK, Frederiksen K, Munk C, Iftner T (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102: 1478-1488.
25. Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W, Snijders JF, Petry KU, Kruger KS, Munk C, Iftner T (2008) Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 80: 1264-1274.
26. Liao SF, Lee WC, Chen HC, Chuang LC, Pan MH, Chen CJ (2012) Baseline human papillomavirus infection, high vaginal parity, and their interaction on cervical cancer risks after a follow-up of more than 10 years. Cancer Causes Control 23: 703-708.
27. Louie KS, de Sanjose S, Diaz M, Castellsague X, Herrero R, Meijer CJ, Shah K, Franceschi S, Munoz N, Bosch FX (2009) Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 100: 1191-1197.
28. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S (2002) Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359: 1085-1092.
29. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJ, Bosch FX (2002) Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359: 1093-1101.
30. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103: 368-383.
31. Smith JS, Green J, Berrington de GA, Appleby P, Peto J, Plummer M, Franceschi S, Beral V (2003) Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361: 1159-1167.
32. Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, Schiffman M, Wacholder S, Allen RA, Block I, Downing K, Jeronimo J, Carreon JD, Safaeian M, Brown D, Walker JL (2009) Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev 18: 113-120.
33. Williams VM, Filippova M, Soto U, Duerksen-Hughes PJ (2011) HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Fut Virol 6: 45-57.